Findings

What do systematic reviews say?

3 questions · 5 findings · 2 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Corticosteroids vs placebo

Caloric extent of recovery (improvement as a % in lateralisation of electronystagmography on caloric testing) · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

2 findings from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low
Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Low

Corticosteroids vs placebo

Complete caloric recovery · Patients with idiopathic acute vestibular dysfunction (vestibular neuritis)

Corticosteroids may leads to higher complete caloric recovery compared with placebo (low certainty).

2 findings from 1 review

Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
RR 2.81 [1.32, 6]
2 studies · 50 participants
Low
Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis) 2011 · Cochrane Headline outcomes only
RR 1.58 [0.45, 5.62]
2 studies · 89 participants
Low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found